ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 80

Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades

Jennifer Rammel1, Patricia Rosillo1, Tiphanie Vogel2 and Marietta de Guzman3, 1Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 2Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, 3Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Adalimumab, anti-TNF therapy, Blau syndrome, infliximab and safety

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:

Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular pathogen sensor, with autosomal dominant inheritance. No therapeutic trials have been conducted in Blau syndrome and only limited case reports regarding treatment are available. The aims of this study were to review the disease course, clinical response, and safety of the prolonged use of biologic medications for seven patients with Blau syndrome.

Methods:

A retrospective chart review was completed with respect to the disease course, treatment regimens, side effects, and therapeutic response of seven patients with Blau syndrome cared for over two decades at Texas Children’s Hospital in Houston, TX.

Results:

Six of the patients are sibling pairs and all had either a sibling and/or parent with Blau syndrome. Six of the patients are male. Age range is 6-22 years. Mean age of symptom onset was 1.3 years and mean age at diagnosis was 5 years. Most of the patients were initially diagnosed as juvenile idiopathic arthritis. Arthritis was present in all patients. Other features varied in frequency: uveitis (n=4), recurrent fever (n=4), and cutaneous involvement (n=4). Initial medications for all patients included NSAIDs and corticosteroids. Additional therapies included methotrexate (86%), cyclosporine (29%), mycophenolate (14%), and azathioprine (14%). Biologic therapy was initiated in all patients and included etanercept (43%), adalimumab (86%), infliximab (57%), abatacept (14%), anakinra (29%), and tocilizumab (29%). Mean duration of therapy in years was etanercept 4.9, adalimumab 2.4, infliximab 3.3, abatacept 0.2, anakinra 3.6, and tocilizumab 0.2. Combined, our center has 43 patient-years of experience with anti-TNF medications in these patients (14.8 years etanercept, 14.6 years adalimumab, and 13.3 years infliximab). Adverse events included liver toxicity (n=2, resolved with stopping concurrent methotrexate), anemia (n=3), thrombocytopenia (n=1), and a benign lung nodule (n=1). Infectious complications occurred in 71%, leading to 4 hospitalizations (cellulitis, cutaneous varicella in two siblings, and bacterial pneumonia). None of these complications warranted a permanent discontinuation of the biologic therapy.

Conclusion:

Blau syndrome is a rare autoinflammatory granulomatous disease that results in significant morbidity if uncontrolled. In our center’s experience with these patients, potent TNF inhibition with infliximab or weekly adalimumab was the most clinically efficacious biologic therapy. There were no serious adverse events warranting permanent discontinuation. These medications should be considered for the treatment of Blau disease.


Disclosure: J. Rammel, None; P. Rosillo, None; T. Vogel, None; M. de Guzman, None.

To cite this abstract in AMA style:

Rammel J, Rosillo P, Vogel T, de Guzman M. Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/treatment-of-blau-syndrome-with-biologic-therapy-a-single-center-case-series-of-seven-patients-over-two-decades/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-blau-syndrome-with-biologic-therapy-a-single-center-case-series-of-seven-patients-over-two-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology